Prevention of mother to child transmission of HIV: Our experience in South India

  • Vijaya Karthekeyani
  • Glory Alexander
  • Eileen Solomon
  • Sarita Rao
  • P. S. S. Sunder Rao
Original Article
  • 25 Downloads

Abstract

Objectives

To determine the outcomes of various ARV (Anti-Retroviral) prophylactic regimes given to HIV positive pregnant mothers, based on time of presentation, for prevention of vertical transmission.

Methods

During a four year period, 92 pregnant HIV positive women and their newborn infants received various ARV prophylactic regimes for prevention of vertical transmission. The outcome, in terms of presence of HIV infection in the infants born to these mothers was studied.

Results

The prevalence of HIV infection in the antenatal group studied was 0.62%. Of the 92 HIV positive pregnant mothers who delivered live babies, 91.3% received ARV prophylaxis or HAART, and 95.6% of the 92 live infants received ARV prophylaxis. The risk of vertical transmission was only 3.3%.

Conclusions

Judicious PMTCT regimes, even if they appear complex, are possible in the Indian setting, and can result in significant decline of HIV positive children. Duration of treatment and mode of delivery should be based on the time of presentation of the HIV positive pregnant mother.

Key Words

HIV mother-to-child transmission vertical transmission zidovudine nevirapine ARV prophylaxis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gupta A, Gupte N, Sastry J et al. Mother-to-child transmission of HIV among women who chose not to exclusively breastfeed their infants in Pune, India. Indian J Med Res 2007;126:131–134.PubMedGoogle Scholar
  2. 2.
    Indian Council of Medical Research. National Institute of Medical Statistics. National AIDS Control Organisation. Technical report — India HIV estimates —2006. New Delhi, ICMR, 2006.Google Scholar
  3. 3.
    Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173–1180.PubMedCrossRefGoogle Scholar
  4. 4.
    Rongkavilit C, Asmar BI. Advances in prevention of mother-to-child HIV transmission. Indian J Pediatr 2004;71:69–79.PubMedCrossRefGoogle Scholar
  5. 5.
    Lallemant M, Jourdain G, Le Coeur S et al. A trial of shortened zidovudine regimens to prevent mother-tochild transmission of human immunodeficiency virus type 1. N Engl J Med 2000;343:982–991.PubMedCrossRefGoogle Scholar
  6. 6.
    Shaffer N, Chuachoowong R, Mock PA et al. Shortcourse zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353:773–780.PubMedCrossRefGoogle Scholar
  7. 7.
    Lallemant M, Jourdain G, Le Coeur S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004;351:217–228.PubMedCrossRefGoogle Scholar
  8. 8.
    Dongoankar D, Taykar AV, Subash AA et al. Perinatal transmission of HIV infection in Mumbai, India. J Obstet Gynaecol India 2001;51:56–60Google Scholar
  9. 9.
    Dongoankar D. Prevention of mother to child transmission of HIV-1 using anti-retroviral drug — Zidovudine. J Obstet Gynaecol India 2003;53:563–567.Google Scholar

Copyright information

© Federation of Obstetrics and Gynaecological Societies of India (FOGSI) 2011

Authors and Affiliations

  • Vijaya Karthekeyani
    • 1
  • Glory Alexander
    • 1
    • 2
  • Eileen Solomon
    • 1
  • Sarita Rao
    • 1
  • P. S. S. Sunder Rao
    • 1
  1. 1.ASHA FoundationBangaloreIndia
  2. 2.ASHA Foundation No.58Anand Nagar, Hebbal, BangaloreIndia

Personalised recommendations